Navigation Links
New bacteria to fight against intestinal inflammation
Date:11/6/2012

This protection is provided by a human protein, Elafin, which is artificially introduced into dairy produce bacteria (Lactococcus lactis and Lactobacillus casei). In time, this discovery could be useful for individuals suffering from chronic inflammatory diseases such as Crohn's disease or ulcerative colitis. The results of this research were published in the Science Translational Medicine review on 31 October 2012.

In France, nearly 200,000 individuals suffer from chronic inflammatory bowel disease, known as IBD, (specifically Crohn's disease and ulcerative colitis). The occurrence rate of this type of disease continues to rise (8,000 new cases diagnosed per year). During inflammatory outbreaks, IBDs are chiefly characterised by abdominal pain, frequent diarrhoea (sometimes with bleeding) or even disorders in the anal area (fissure, abscesses). These symptoms mean that taboos are associated with these diseases.

Different avenues are being explored to explain the origin of IBDs, including the role of genetic or environmental factors. The intestinal flora seems to play an important role in the outbreak of inflammation, although little is known about it. Identifying an effective treatment is also at the heart of the investigations.

Researchers are focussing on a human protein, known for its anti-inflammatory proprieties: Elafin. Although this protein is found naturally in the intestine to protect it against attacks, it disappears in patients suffering from IBDs.

Their hypothesis? Administering Elafin directly into the intestine could protect against inflammatory attacks and restore intestinal equilibrium and its functions.

Using non-pathogenic bacteria found naturally in the intestine and food, scientists from Inserm and Inra have designed modified bacteria to produce Elafin. To this end, the human Elafin gene, isolated in collaboration with a team from the Institut Pasteau, was introduced in Lactococcus lactis and Lactobacillus casei, two food-grade bacteria found in dairy products.

Results in mice

When administered orally to mice, the human Elafin-producing bacteria are found a few hours later on the surface of the intestine where they deliver the anti-inflammatory protein. In different mice models of chronic or acute intestinal inflammation, oral treatment using these Elafin-producing bacteria provided significant protection of the intestine and decreased inflammatory symptoms.

and in humans

Elafin expressed by these bacteria also protects cultured human intestinal cell lines from inflammatory outbreaks similar to those observed in chronic inflammatory bowel diseases. Elafin produced in this way restores the equilibrium of intestinal mucus by reducing inflammation and accelerating cell healing processes.

Potential clinical applications

These results may result in a clinical application where Elafin would be administered to patients suffering from IBDs using beneficial bacteria (probiotic), which are already commonly found in food (yoghurt, cheese), thus protecting the patients from inflammatory symptoms. According to the researchers "This kind of secure treatment could even be used over the long-term, to treat inflammatory diseases."


'/>"/>

Contact: Press Office
presse@inserm.fr
INSERM (Institut national de la sant et de la recherche mdicale)
Source:Eurekalert

Related medicine news :

1. Bacteria Found in Other Products From Firm Tied to Meningitis Outbreak: FDA
2. Crohns Disease in Children May Start From Bacteria
3. Scientists step up hunt for bacterial genes tied to Lyme disease
4. Oral bacteria may signal pancreatic cancer risk
5. Discovery of essential genes for drug-resistant bacteria reveals new, high-value drug targets
6. Superpowered Bacteria May Lurk Behind Sinus Infections
7. Feces-Linked Bacteria Found at Lake Erie Beaches
8. Could Bacteria in Skin Mites Help Cause Rosacea?
9. New antibacterial coating for sutures could reduce infections after surgery
10. Trudeau researchers identify unforeseen regulation of the anti-bacterial immune response
11. Microbiology and Genome Experts Quell Deadly Bacteria Outbreak
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology: